非心源性缺血性卒中及短暂性脑缺血发作患者的抗血小板治疗

摘要

在脑血管病患者中,约80%为缺血性卒中患者,多伴有多种危险因素,是卒中复发的高危人群.在非心源性缺血性卒中/短暂性脑缺血发作(transient ischemic attack,TIA)的二级预防中,抗血小板治疗的疗效已被大量临床研究证实,并被各国的指南所推荐.本文结合新近发表的指南以及经典的临床试验,对非心源性缺血性卒中/TIA的抗血小板治疗模式做一综述.%In all patients with cerebrovascular disease, ischemic stroke accounts for about 80％. Moreover, ischemic stroke patients, many of whom accompanied by multiple risk factors suffer high risk of stroke recurrence. In the secondary prevention of non-cardiac ischemic stroke / transient ischemic attack (TIA), the efficacy of anti-platelet therapy has been verified by a large number of clinical studies, and was recommended by national guidelines of many countries.According to recent guideline and classical clinical trials, we make a review about the model of antiplatelet therapy for ischemic stroke or TIA of non-cardiac origin.